







Amendments to the Claims:

1. (original) A method of treating cognition deficit disorders comprising administering to a mammal in need of such treatment an effective amount of a dual histamine H<sub>3</sub> receptor antagonist / m<sub>2</sub> muscarinic antagonist.
2. (original) The method of claim 1 wherein the dual H<sub>3</sub>/m<sub>2</sub> antagonist is selected from the group consisting of






AI



and



Claims 3 to 13 (withdrawn)

14. (currently amended) A method of treating cognition deficit disorders comprising administering to a mammal in need of such treatment an effective amount of a dual histamine H<sub>3</sub> antagonist/m<sub>2</sub> muscarinic antagonist ~~or an effective amount of a combination of a histamine H<sub>3</sub> receptor antagonist and a m<sub>2</sub> muscarinic antagonist~~, in combination with an effective amount of an acetylcholinesterase inhibitor.

AI 15. (currently amended) A pharmaceutical composition comprising an effective amount of a dual histamine H<sub>3</sub> antagonist/ m<sub>2</sub> muscarinic antagonist ~~or a combination of a histamine H<sub>3</sub> antagonist and a m<sub>2</sub> muscarinic antagonist~~, in further combination with an acetylcholinesterase inhibitor and a pharmaceutically acceptable carrier.

16. (withdrawn)

---